Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?
作者信息
Stevens Michael P, Patel Payal K, Nori Priya
机构信息
Healthcare Infection Prevention Department, Virginia Commonwealth University Health System, Richmond, Virginia.
Infectious Diseases Section, Ann Arbor VA Medical Center, Ann Arbor, Michigan.
出版信息
Infect Control Hosp Epidemiol. 2021 Sep;42(9):1153-1154. doi: 10.1017/ice.2020.459. Epub 2020 Sep 9.
Abstract
摘要
相似文献
1
Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?针对2019冠状病毒病的抗菌药物管理计划和恢复期血浆：预授权的新范例？
Infect Control Hosp Epidemiol. 2021 Sep;42(9):1153-1154. doi: 10.1017/ice.2020.459. Epub 2020 Sep 9.
2
[COVID-19: Still a place for the convalescent plasma? Focus on the immunocompromised patients].[新型冠状病毒肺炎：恢复期血浆疗法仍有应用空间？聚焦免疫功能低下患者]
Rev Med Interne. 2023 Sep;44(9):467-471. doi: 10.1016/j.revmed.2023.08.005. Epub 2023 Sep 7.
3
Convalescent plasma for COVID-19 considerations.关于新冠病毒病恢复期血浆的考量
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.
4
[Is convalescent plasma an alternative treatment for Covid-19 patients?].[康复期血浆是新冠病毒肺炎患者的替代治疗方法吗？]
Salud Publica Mex. 2020 Nov-Dec;62(6):870-871. doi: 10.21149/11744.
5
Covid-19 convalescent plasma and SARS-CoV-2 viral variants.新冠康复者血浆与严重急性呼吸综合征冠状病毒2病毒变体
Transfus Clin Biol. 2021 Aug;28(3):306. doi: 10.1016/j.tracli.2021.05.008. Epub 2021 May 29.
6
Rethinking the role of COVID-19 convalescent plasma in the critically ill.重新思考新冠康复者血浆在危重症患者中的作用。
Transfus Apher Sci. 2023 Feb;62(1):103521. doi: 10.1016/j.transci.2022.103521. Epub 2022 Aug 4.
7
Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.用于治疗新冠病毒肺炎的康复期血浆——解读其中的不一致之处
N Engl J Med. 2022 May 5;386(18):1753-1754. doi: 10.1056/NEJMe2204332.
8
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.康复期血浆和SARS-CoV-2高免疫静脉注射人免疫球蛋白对循环中的SARS-CoV-2德尔塔和奥密克戎变体的中和作用用于治疗新冠肺炎。
Ann Rheum Dis. 2022 Jul;81(7):1044-1045. doi: 10.1136/annrheumdis-2022-222115. Epub 2022 Feb 10.
9
Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors.重复恢复期血浆捐献者体内抗SARS-CoV-2抗体的动态变化
Transfus Apher Sci. 2021 Dec;60(6):103216. doi: 10.1016/j.transci.2021.103216. Epub 2021 Jul 22.
10
A look-back at convalescent plasma to treat COVID-19.回顾恢复期血浆治疗新冠病毒病
Transfus Apher Sci. 2021 Feb;60(1):103063. doi: 10.1016/j.transci.2021.103063. Epub 2021 Jan 12.
引用本文的文献
1
Leveraging antimicrobial stewardship programs in response to the coronavirus disease 2019 (COVID-19) public health emergency.利用抗菌药物管理计划应对2019冠状病毒病（COVID-19）公共卫生紧急情况。
Antimicrob Steward Healthc Epidemiol. 2022 Mar 14;2(1):e41. doi: 10.1017/ash.2022.34. eCollection 2022.
2
COVID-19 and antimicrobial stewardship: lessons learned, best practices, and future implications.COVID-19 与抗菌药物管理：经验教训、最佳实践和未来影响。
Int J Infect Dis. 2021 Dec;113:103-108. doi: 10.1016/j.ijid.2021.10.001. Epub 2021 Oct 5.
3
Pandemic stewardship: Reflecting on new roles and contributions of antimicrobial stewardship programs during the coronavirus disease 2019 (COVID-19) pandemic.大流行管理：反思抗菌药物管理计划在2019冠状病毒病（COVID-19）大流行期间的新角色和贡献。
Infect Control Hosp Epidemiol. 2022 Aug;43(8):1085-1086. doi: 10.1017/ice.2021.172. Epub 2021 Apr 16.
4
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.恢复期血浆用于 COVID-19 的预防和治疗：系统评价和定量分析。
JMIR Public Health Surveill. 2021 Apr 7;7(4):e25500. doi: 10.2196/25500.
5
Coronavirus disease 2019 (COVID-19) research agenda for healthcare epidemiology.2019 年冠状病毒病（COVID-19）医疗流行病学研究议程。
Infect Control Hosp Epidemiol. 2022 Feb;43(2):156-166. doi: 10.1017/ice.2021.25. Epub 2021 Jan 25.
6
Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development.中东呼吸综合征、严重急性呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒2的比较与对比：预防、传播、管理及疫苗研发
Pathogens. 2020 Nov 26;9(12):985. doi: 10.3390/pathogens9120985.
本文引用的文献
1
Antimicrobial Stewardship at the Core of COVID-19 Response Efforts: Implications for Sustaining and Building Programs.抗菌药物管理是新冠疫情应对工作的核心：对维持和建立相关项目的启示
Curr Infect Dis Rep. 2020;22(9):23. doi: 10.1007/s11908-020-00734-x. Epub 2020 Jul 3.
2
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
3
Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck.让抗菌药物管理计划参与到应对新冠疫情的工作中：全员出动。
Infect Control Hosp Epidemiol. 2020 Jun;41(6):744-745. doi: 10.1017/ice.2020.69.
4
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.美国传染病学会和美国医疗保健流行病学学会关于制定机构计划以加强抗菌药物管理的指南。
Clin Infect Dis. 2007 Jan 15;44(2):159-77. doi: 10.1086/510393. Epub 2006 Dec 13.
Zotero 插件